newsfilter
← Latest News
GlobeNewswire·

Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000

MALVERN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for acute care settings, today announced that the first cohort has been dosed in a First-in-Man, Phase 1 clinical stu